EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C26H29NO |
| Net Charge | 0 |
| Average Mass | 371.524 |
| Monoisotopic Mass | 371.22491 |
| SMILES | CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1 |
| InChI | InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- |
| InChIKey | NKANXQFJJICGDU-QPLCGJKRSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Roles: | estrogen receptor antagonist An antagonist at the estrogen receptor. EC 2.7.11.13 (protein kinase C) inhibitor An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13). anti-HIV agent An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. EC 1.2.3.1 (aldehyde oxidase) inhibitor An EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor which interferes with the action of aldehyde oxidase (EC 1.2.3.1). antiviral agent A substance that destroys or inhibits replication of viruses. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. estrogen antagonist A compound which inhibits or antagonises the biosynthesis or actions of estrogens. |
| Applications: | estrogen receptor antagonist An antagonist at the estrogen receptor. angiogenesis inhibitor An agent and endogenous substances that antagonize or inhibit the development of new blood vessels. antifibrotic agent Any agent which acts to reduce fibrosis. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. antipsychotic agent Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. estrogen receptor modulator A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure. estrogen antagonist A compound which inhibits or antagonises the biosynthesis or actions of estrogens. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| tamoxifen (CHEBI:41774) has parent hydride stilbene (CHEBI:26775) |
| tamoxifen (CHEBI:41774) has role analgesic (CHEBI:35480) |
| tamoxifen (CHEBI:41774) has role angiogenesis inhibitor (CHEBI:48422) |
| tamoxifen (CHEBI:41774) has role anti-HIV agent (CHEBI:64946) |
| tamoxifen (CHEBI:41774) has role antifibrotic agent (CHEBI:233423) |
| tamoxifen (CHEBI:41774) has role antihypertensive agent (CHEBI:35674) |
| tamoxifen (CHEBI:41774) has role antineoplastic agent (CHEBI:35610) |
| tamoxifen (CHEBI:41774) has role antipsychotic agent (CHEBI:35476) |
| tamoxifen (CHEBI:41774) has role antiviral agent (CHEBI:22587) |
| tamoxifen (CHEBI:41774) has role bone density conservation agent (CHEBI:50646) |
| tamoxifen (CHEBI:41774) has role cardiovascular drug (CHEBI:35554) |
| tamoxifen (CHEBI:41774) has role EC 1.2.3.1 (aldehyde oxidase) inhibitor (CHEBI:62872) |
| tamoxifen (CHEBI:41774) has role EC 2.7.11.13 (protein kinase C) inhibitor (CHEBI:37700) |
| tamoxifen (CHEBI:41774) has role estrogen antagonist (CHEBI:50837) |
| tamoxifen (CHEBI:41774) has role estrogen receptor antagonist (CHEBI:50792) |
| tamoxifen (CHEBI:41774) has role estrogen receptor modulator (CHEBI:50739) |
| tamoxifen (CHEBI:41774) is a stilbenoid (CHEBI:26776) |
| tamoxifen (CHEBI:41774) is a tertiary amino compound (CHEBI:50996) |
| Incoming Relation(s) |
| afimoxifene (CHEBI:44616) has functional parent tamoxifen (CHEBI:41774) |
| tamoxifen N-oxide (CHEBI:63825) has functional parent tamoxifen (CHEBI:41774) |
| tamoxifen citrate (CHEBI:9397) has part tamoxifen (CHEBI:41774) |
| IUPAC Name |
|---|
| 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine |
| INNs | Source |
|---|---|
| tamoxifen | ChemIDplus |
| tamoxifène | ChemIDplus |
| tamoxifeno | ChemIDplus |
| tamoxifenum | ChemIDplus |
| Synonyms | Source |
|---|---|
| 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene | ChemIDplus |
| 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene | ChemIDplus |
| ICI-47699 | ChEMBL |
| Mammaton | ChEMBL |
| Novaldex | ChEMBL |
| NSC-727681 | ChEMBL |
| Brand Names | Source |
|---|---|
| Apo-Tamox | DrugBank |
| Citofen | DrugBank |
| Crisafeno | DrugBank |
| Diemon | DrugBank |
| Gen-Tamoxifen | DrugBank |
| Istubol | DrugBank |
| Registry Numbers | Sources |
|---|---|
| Beilstein:2062020 | Beilstein |
| CAS:10540-29-1 | KEGG COMPOUND |
| CAS:10540-29-1 | ChemIDplus |
| Citations |
|---|